Zhongwei Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhongwei Zhao has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jiansong Ji
Department of Radiology, Lishui Hospital of Zhejiang University, Lishui, China
6 shared publications - Minjiang Chen
Department of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
4 shared publications - Gaofeng Shu
Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research The Fifth Affiliated Hospital of Wenzhou Medical University Lishui China
3 shared publications - Jianfei Tu
Ningbo University
3 shared publications - Jingjing Song
Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Affiliated Lishui Hospital of Zhejiang University, The Central Hospital of Zhejiang Lishui, Lishui, 323000, China; Department of Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, Affiliated Lishui Hospital of Zhejiang University, The Central Hospital of Zhejiang Lishui, Lishui, 323000, China
3 shared publications - Weiqian Chen
Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 shared publications
Latest Publications
- Open Access
- 10 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Bacillus coagulans MZY531 alleviates intestinal mucosal injury in immunosuppressive mice via modulating intestinal barrier, inflammatory response, and gut microbiota
Bacillus coagulans has a potential role in improving intestinal injury. However, the specific mechanism is still unclear. In this study, the protective effect of B. coagulans MZY531 on intestinal mucosa injury in cyclophosphamide (CYP)-induced immunosuppressed mice were investigated. The results indicated that the immune organ (thymus and spleen) indices of B. coagulans MZY531 treatment groups were significantly increased compared to the CYP group. B. coagulans MZY531 administration promotes the expression of immune proteins (IgA, IgE, IgG, and IgM). B. coagulans MZY531 could upregulate the ileum levels of IFN-γ, IL-2, IL-4, and IL-10 in immunosuppressed mice. Moreover, B. coagulans MZY531 restores the villus height and crypt depth of the jejunum and alleviates injury of intestinal endothelial cells caused by CYP. Furthermore, the western blotting results showed that B. coagulans MZY531 ameliorated CYP-induced intestinal mucosal injury and inflammatory via up-regulates the ZO-1 pathway and down-regulates the expression of the TLR4/MyD88/NF-κB pathway. After treatment with B. coagulans MZY531, the relative abundance of Firmicutes phylum was dramatically increased, as well as the genera of Prevotella and Bifidobacterium, and reducing harmful bacteria. These findings suggested that B. coagulans MZY531 has a potential immunomodulatory activity on chemotherapy-induced immunosuppression.
- 10 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessBacillus coagulans MZY531 alleviates intestinal mucosal injury in immunosuppressive mice via modulating intestinal barrier, inflammatory response, and gut microbiota
Bacillus coagulans has a potential role in improving intestinal injury. However, the specific mechanism is still unclear. In this study, the protective effect of B. coagulans MZY531 on intestinal mucosa injury in cyclophosphamide (CYP)-induced immunosuppressed mice were investigated. The results indicated that the immune organ (thymus and spleen) indices of B. coagulans MZY531 treatment groups were significantly increased compared to the CYP group. B. coagulans MZY531 administration promotes the expression of immune proteins (IgA, IgE, IgG, and IgM). B. coagulans MZY531 could upregulate the ileum levels of IFN-γ, IL-2, IL-4, and IL-10 in immunosuppressed mice. Moreover, B. coagulans MZY531 restores the villus height and crypt depth of the jejunum and alleviates injury of intestinal endothelial cells caused by CYP. Furthermore, the western blotting results showed that B. coagulans MZY531 ameliorated CYP-induced intestinal mucosal injury and inflammatory via up-regulates the ZO-1 pathway and down-regulates the expression of the TLR4/MyD88/NF-κB pathway. After treatment with B. coagulans MZY531, the relative abundance of Firmicutes phylum was dramatically increased, as well as the genera of Prevotella and Bifidobacterium, and reducing harmful bacteria. These findings suggested that B. coagulans MZY531 has a potential immunomodulatory activity on chemotherapy-induced immunosuppression.
- 4 January 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 231, 123160
Monodisperse CaCO3-loaded gelatin microspheres for reversing lactic acid-induced chemotherapy resistance during TACE treatment
- 4 January 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 231, 123160
Monodisperse CaCO3-loaded gelatin microspheres for reversing lactic acid-induced chemotherapy resistance during TACE treatment
- 31 October 2022
- Published by Elsevier in Applied Surface Science
- Vol. 610
Intrinsic oxygen defects in UO2 (1 1 1) and PuO2 (1 1 1) surfaces
- 31 October 2022
- Published by Elsevier in Applied Surface Science
- Vol. 610
Intrinsic oxygen defects in UO2 (1 1 1) and PuO2 (1 1 1) surfaces
- Open Access
- 14 October 2022
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 17 (6) , 908-923
Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery
- 14 October 2022
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 17 (6) , 908-923
Open AccessFucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery
- 22 February 2022
- Published by Elsevier in Pharmacological Research
- Vol. 177, 106140
Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer
- 22 February 2022
- Published by Elsevier in Pharmacological Research
- Vol. 177, 106140
Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer
- 17 June 2019
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 147 (1) , 29-35
Short‐term efficacy, safety, and cost‐effectiveness of transarterial chemoembolization with drug‐eluting beads versus synchronous radiochemotherapy for cervical cancer
Objective: To investigate the short‐term efficacy and safety of transarterial chemoembolization with drug‐eluting beads (DEB‐TACE) versus synchronous radiochemotherapy among women with cervical cancer.Methods: A retrospective cohort study of women treated by synchronous radiochemotherapy (n=20) and DEB‐TACE (n=20) at a single center in China between November 2015 and September 2017. Inclusion criteria were pathologic diagnosis of cervical cancer, age at least 18 years, and complete clinicopathologic information. Hospital stay, direct medical cost, resection frequency, adverse events, treatment responses, progression‐free survival (PFS) and overall survival (OS) were compared between treatments.Results: There was no difference in treatment responses, PFS, or OS between the two groups. Hospital stay was shorter, direct medical costs were lower, and resection rate was higher in the DEB‐TACE group than in the radiochemotherapy group (all P<0.05). In univariate and multivariate logistic regression analysis, no factor was associated with complete response. No predictive factor for PFS or OS was identified by Cox proportional regression analysis. Fewer adverse advents were recorded in the DEB‐TACE group than in the synchronous radiochemotherapy group.Conclusion: Among women with cervical cancer, DEB‐TACE achieved equal short‐term efficacy, better tolerance, less hospital stay and medical costs, and higher resection rates as compared with synchronous radiochemotherapy.
- 17 June 2019
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 147 (1) , 29-35
Short‐term efficacy, safety, and cost‐effectiveness of transarterial chemoembolization with drug‐eluting beads versus synchronous radiochemotherapy for cervical cancer
Objective: To investigate the short‐term efficacy and safety of transarterial chemoembolization with drug‐eluting beads (DEB‐TACE) versus synchronous radiochemotherapy among women with cervical cancer.Methods: A retrospective cohort study of women treated by synchronous radiochemotherapy (n=20) and DEB‐TACE (n=20) at a single center in China between November 2015 and September 2017. Inclusion criteria were pathologic diagnosis of cervical cancer, age at least 18 years, and complete clinicopathologic information. Hospital stay, direct medical cost, resection frequency, adverse events, treatment responses, progression‐free survival (PFS) and overall survival (OS) were compared between treatments.Results: There was no difference in treatment responses, PFS, or OS between the two groups. Hospital stay was shorter, direct medical costs were lower, and resection rate was higher in the DEB‐TACE group than in the radiochemotherapy group (all P<0.05). In univariate and multivariate logistic regression analysis, no factor was associated with complete response. No predictive factor for PFS or OS was identified by Cox proportional regression analysis. Fewer adverse advents were recorded in the DEB‐TACE group than in the synchronous radiochemotherapy group.Conclusion: Among women with cervical cancer, DEB‐TACE achieved equal short‐term efficacy, better tolerance, less hospital stay and medical costs, and higher resection rates as compared with synchronous radiochemotherapy.
- Open Access
- 14 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (16) , 22186-22192
SMAD7 loci contribute to risk of hepatocellular carcinoma and clinicopathologic development among Chinese Han population
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jiansong Ji1, *, Min Xu1, *, Zhongwei Zhao1, *, Jianfei Tu1, *, Jun Gao2, *, Chenying Lu1, Jingjing Song1, Weiqian Chen1, Minjiang Chen1, Xiaoxi Fan1, Xingyao Cheng1, Xilin Lan1, Jie Li3 1Department of Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University/Affiliated Lishui Hospital of Zhejiang University/The Central Hospital of Zhejiang Lishui, Lishui, Zhejiang, P.R. China 2Department of Hepatobiliary Surgery, Beijing Chao-yang Hospital Affiliated with Capital Medical University, Beijing, P.R. China 3The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China *These authors contributed equally to this work Correspondence to: Jiansong Ji, e-mail: jijiansongzjls@163.com Keywords: HCC, mothers against decapentaplegic homolog 7 (SMAD7), transforming growth factor beta (TGF-β), risk, SNP Received: November 05, 2015 Accepted: February 05, 2016 Published: March 14, 2016 ABSTRACT Genome-wide association studies (GWAS) have identified three loci at 18q21 (rs4939827, rs7240004, and rs7229639), which maps to SMAD7 loci, were associated with risk of diseases of the digestive system. However, their associations with hepatocellular carcinoma (HCC) risk remain unknown. A case-control study was conducted to assess genetic associations with HCC risk and clinicopathologic development among Chinese Han population. Three SNPs were genotyped among 1,000 HCC cases and 1,000 controls using Sequenom Mass-ARRAY technology. We observed statistically significant associations for the three SMAD7 loci and HCC risk. Each copy of minor allele was associated with a 1.24–1.36 fold increased risk of HCC. We also found that significant differences were observed between rs4939827 and clinical TNM stage and vascular invasion, as well as rs7240004 and vascular invasion. We also established a genetic risk score (GRS) by summing the risk alleles. The GRS was significantly associated with increased risk of HCC and vascular invasion. Our data revealed the SMAD7 loci is associated with HCC susceptibility and its clinicopathologic development.
- 14 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (16) , 22186-22192
Open AccessSMAD7 loci contribute to risk of hepatocellular carcinoma and clinicopathologic development among Chinese Han population
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jiansong Ji1, *, Min Xu1, *, Zhongwei Zhao1, *, Jianfei Tu1, *, Jun Gao2, *, Chenying Lu1, Jingjing Song1, Weiqian Chen1, Minjiang Chen1, Xiaoxi Fan1, Xingyao Cheng1, Xilin Lan1, Jie Li3 1Department of Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University/Affiliated Lishui Hospital of Zhejiang University/The Central Hospital of Zhejiang Lishui, Lishui, Zhejiang, P.R. China 2Department of Hepatobiliary Surgery, Beijing Chao-yang Hospital Affiliated with Capital Medical University, Beijing, P.R. China 3The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China *These authors contributed equally to this work Correspondence to: Jiansong Ji, e-mail: jijiansongzjls@163.com Keywords: HCC, mothers against decapentaplegic homolog 7 (SMAD7), transforming growth factor beta (TGF-β), risk, SNP Received: November 05, 2015 Accepted: February 05, 2016 Published: March 14, 2016 ABSTRACT Genome-wide association studies (GWAS) have identified three loci at 18q21 (rs4939827, rs7240004, and rs7229639), which maps to SMAD7 loci, were associated with risk of diseases of the digestive system. However, their associations with hepatocellular carcinoma (HCC) risk remain unknown. A case-control study was conducted to assess genetic associations with HCC risk and clinicopathologic development among Chinese Han population. Three SNPs were genotyped among 1,000 HCC cases and 1,000 controls using Sequenom Mass-ARRAY technology. We observed statistically significant associations for the three SMAD7 loci and HCC risk. Each copy of minor allele was associated with a 1.24–1.36 fold increased risk of HCC. We also found that significant differences were observed between rs4939827 and clinical TNM stage and vascular invasion, as well as rs7240004 and vascular invasion. We also established a genetic risk score (GRS) by summing the risk alleles. The GRS was significantly associated with increased risk of HCC and vascular invasion. Our data revealed the SMAD7 loci is associated with HCC susceptibility and its clinicopathologic development.
- Open Access
- 22 February 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (13) , 16593-16609
Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation
Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation
- 22 February 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (13) , 16593-16609
Open AccessSelective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation
Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation